Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

BACKGROUND: To determine the safety and efficacy of the anti-colony-stimulating factor 1 receptor (anti-CSF1R) monoclonal antibody AMG 820 in combination with pembrolizumab in patients with select solid tumors. PATIENTS AND METHODS: Patients had advanced, refractory mismatch repair-proficient colore...

Descripción completa

Detalles Bibliográficos
Autores principales: Razak, Albiruni RA, Cleary, James M, Moreno, Victor, Boyer, Michael, Calvo Aller, Emiliano, Edenfield, William, Tie, Jeanne, Harvey, R Donald, Rutten, Annemie, Shah, Manish A, Olszanski, Anthony J, Jäger, Dirk, Lakhani, Nehal, Ryan, David P, Rasmussen, Erik, Juan, Gloria, Wong, Hansen, Soman, Neelesh, Smit, Marie-Anne Damiette, Nagorsen, Dirk, Papadopoulos, Kyriakos P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552843/
https://www.ncbi.nlm.nih.gov/pubmed/33046621
http://dx.doi.org/10.1136/jitc-2020-001006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552843/
https://www.ncbi.nlm.nih.gov/pubmed/33046621
http://dx.doi.org/10.1136/jitc-2020-001006

Ejemplares similares